Some investigation implies that CBD could possibly have neuroprotective properties, possibly benefiting conditions like epilepsy and neurodegenerative Diseases. In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they intend to reclassify cannabis being a Schedule III drug